BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol 2018; 10(5): 108-114 [PMID: 29770170 DOI: 10.4251/wjgo.v10.i5.108]
URL: https://www.wjgnet.com/1007-9327/full/v10/i5/108.htm
Number Citing Articles
1
Tae Ho Hong, M. T. Jeena, Ok-Hee Kim, Kee-Hwan Kim, Ho Joong Choi, Kyung Hee Lee, Ha-Eun Hong, Ja-Hyoung Ryu, Say-June Kim. Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cellsScientific Reports 2021; 11(1) doi: 10.1038/s41598-020-79536-z
2
Hong‐fu Liu, Yuan‐kang Xie, Bai‐yin Zhong, Jian‐hong Zhang, Cai‐xin Song, Yu‐wen Liu, Yan Yang, Bin‐hui Xie. Dipeptidyl peptidase‐8 induces sorafenib resistance via binding with c‐Rel to mediate NF‐κB signaling in hepatocellular carcinomaCell Biology International 2022; 46(2): 213 doi: 10.1002/cbin.11719
3
H.H. Rashwan, A.M. Taher, H.A. Hassan, A.A. Awaji, C.J. Kiriacos, R.A. Assal, R.A. Youness. Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignanciesPathology - Research and Practice 2024; 256: 155223 doi: 10.1016/j.prp.2024.155223
4
Shima Ghavimi, Tehila Apfel, Hamed Azimi, Alana Persaud, Nikolaos T. Pyrsopoulos. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future OptionsJournal of Clinical and Translational Hepatology 2020; 8(2): 168 doi: 10.14218/JCTH.2020.00001
5
Yong Zhou, Ren-Gen Fan, Cheng-Lin Qin, Jing Jia, Xu-Dong Wu, Wen-Zhang Zha. LncRNA-H19 activates CDC42/PAK1 pathway to promote cell proliferation, migration and invasion by targeting miR-15b in hepatocellular carcinomaGenomics 2019; 111(6): 1862 doi: 10.1016/j.ygeno.2018.12.009
6
Jonathan Tibballs, Warren Clements. Immunotherapy and Transarterial therapy of HCC: What the interventional radiologist needs to know about the changing landscape of HCC treatment?Journal of Medical Imaging and Radiation Oncology 2022; 66(4): 478 doi: 10.1111/1754-9485.13405
7
Shengnan Liu, Yang Du, He Ma, Qian Liang, Xu Zhu, Jie Tian. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imagingCancer Letters 2019; 453: 74 doi: 10.1016/j.canlet.2019.03.037
8
Zhaonan Liu, Xingjie Li, Xuequn He, Yingchun Xu, Xi Wang. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case reportBMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6287-8
9
Weiwei Ke, Hongbo Wang, Xiangxuan Zhao, Zaiming Lu. Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinomaFood & Function 2021; 12(4): 1482 doi: 10.1039/D0FO02243H
10
Mengmeng Wang, Zhifan Xiong. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular CarcinomaInternational Journal of General Medicine 2021; : 6343 doi: 10.2147/IJGM.S333390
11
Xiaohong Cen, Kui Cheng. Ter‐cell, A New Target for Hepatocellular Carcinoma TherapyChemBioChem 2018; 19(21): 2254 doi: 10.1002/cbic.201800410
12
Innere Medizin Differenzialdiagnostik und Differenzialtherapie2021; : 503 doi: 10.1016/B978-3-437-21921-4.00246-4
13
Jun-Shan Liu, Chu-Ying Huo, Hui-Hui Cao, Chun-Lin Fan, Jian-Yang Hu, Li-Juan Deng, Zi-Bin Lu, Hua-Yi Yang, Lin-Zhong Yu, Zhi-Xian Mo, Zhi-Ling Yu. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathwayPhytomedicine 2019; 61: 152843 doi: 10.1016/j.phymed.2019.152843
14
Yang Shi, Xiaohua Yang, Xiaofeng Xue, Ding Sun, Peng Cai, Qingwei Song, Bin Zhang, Lei Qin. HANR promotes lymphangiogenesis of hepatocellular carcinoma via secreting miR‐296 exosome and regulating EAG1/VEGFA signaling in HDLEC cellsJournal of Cellular Biochemistry 2019; 120(10): 17699 doi: 10.1002/jcb.29036
15
Yu-Chen Chuang, Jen-Chih Tseng, Li-Rung Huang, Chun-Ming Huang, Chi-Ying F. Huang, Tsung-Hsien Chuang. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint BlockadeFrontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.01075
16
Yongzheng Xu, Chuandong Sun, Bing Han, Yue Xi, Mao Zhang, Jing Yang, Zongkai Chen. High KIAA1522 expression predicts a poor prognosis in patients with hepatocellular carcinomaOncology Letters 2020; 20(1): 509 doi: 10.3892/ol.2020.11588
17
Qing‐Quan Liu, Yu‐Wen Liu, Yuan‐Kang Xie, Jian‐Hong Zhang, Cai‐Xin Song, Jian‐Zhong Wang, Bin‐Hui Xie. Amplification of DDR2 mediates sorafenib resistance through NF‐κB/c‐Rel signaling in hepatocellular carcinomaCell Biology International 2021; 45(9): 1906 doi: 10.1002/cbin.11625
18
T. Mocan, Z. Sparchez, R. Craciun, C. N. Bora, D. C. Leucuta. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectivesClinical and Translational Oncology 2019; 21(6): 702 doi: 10.1007/s12094-018-1975-4
19
Mahmoud A. Younis, Ikramy A. Khalil, Mahmoud M. Abd Elwakil, Hideyoshi Harashima. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer CellsMolecular Pharmaceutics 2019; 16(9): 4031 doi: 10.1021/acs.molpharmaceut.9b00738
20
Lincy S. Lal, Abdalla Aly, Lisa B. Le, Susan Peckous, Brian Seal, April Teitelbaum. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims studyCancer Reports 2022; 5(5) doi: 10.1002/cnr2.1504
21
Zhi Liu, Jian Yu Chen, Yang Zhong, Liang Xie, Jian Shui Li. lncRNA MEG3 inhibits the growth of hepatocellular carcinoma cells by sponging miR-9-5p to upregulate SOX11Brazilian Journal of Medical and Biological Research 2019; 52(10) doi: 10.1590/1414-431x20198631
22
Ching Ngar Wong, Petros Fessas, Kathy Dominy, Francesco A. Mauri, Takahiro Kaneko, Persephone Du Parcq, Jamshid Khorashad, Pierluigi Toniutto, Robert D. Goldin, Claudio Avellini, David J. Pinato. Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinomaLiver International 2021; 41(1): 192 doi: 10.1111/liv.14706